New therapeutic agents for the treatment of asthma and COPD: PDE4 inhibitors, atropine derivatives and corticosteroids

被引：0

作者：

de Blay, F ^{[1
]}

Barnig, C ^{[1
]}

机构：

[1] Univ Strasbourg 1, Unite Pneumol Gen Asthmol & Allergol, Dept Pneumol, Hop Univ Strasbourg,EA 3371, F-67091 Strasbourg, France

来源：

REVUE FRANCAISE D ALLERGOLOGIE ET D IMMUNOLOGIE CLINIQUE | 2006年 / 46卷 / 03期

关键词：

asthma; COPD; therapy; PDE4; inhibitors; roflumilast; cilomilast; ciclesonide; tiotropium;

D O I：

10.1016/j.allerg.2006.01.013

中图分类号：

R392 [医学免疫学];

学科分类号：

100102 ;

摘要：

This review presents recent data on new therapeutic agents for the treatment of asthma and chronic obstructive pulmonary disease (COPD). Type 4-phosphodiesterase inhibitors, in particular roflumilast, seem to have an effect on the immediate and delayed bronchial response and on FEV1 in asthmatics. Ciclesonide is a novel inhaled corticosteroid that appears interesting because of its long lasting effect and its better local and systemic safety profile. Tiotropium bromide is a new long-acting inhaled anti-cholinergic bronchodilator approved for once-daily, long-term treatment in COPD; it is of has a particular interest because of its effect on FEV1. Generally, these three new therapeutic agents are meant to be used in the treatment of asthma and COPD in combination with other drugs. (c) 2006 Elsevier SAS. Tous droits reserves.

引用

页码：252 / 256

页数：5

共 54 条

[1] New drugs for asthma [J].

Barnes, PJ .

NATURE REVIEWS DRUG DISCOVERY, 2004, 3 (10) :831-844

[2] Inhaled tiotropium for stable chronic obstructive pulmonary disease - art. no. CD002876.pub2 [J].

Barr, RG ;

Bourbeau, J ;

Camargo, CA ;

Ram, FSF .

COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2005, (02)

[3] Preclinical profile of ciclesonide, a novel corticosteroid for the treatment of asthma [J].

Belvisi, MG ;

Bundschuh, DS ;

Stoeck, M ;

Wicks, S ;

Underwood, S ;

Battram, CH ;

Haddad, EB ;

Webber, SE ;

Foster, ML .

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2005, 314 (02) :568-574

[4] Comparison of roflumilast, an oral anti-inflammatory, with beclomethasone dipropionate in the treatment of persistent asthma [J].

Bousquet, J ;

Aubier, M ;

Sastre, J ;

Izquierdo, JL ;

Adler, LM ;

Hofbauer, P ;

Rost, KD ;

Harnest, U ;

Kroemer, B ;

Albrecht, A ;

Bredenbröker, D .

ALLERGY, 2006, 61 (01) :72-78

[5] Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD [J].

Brusasco, V ;

Hodder, R ;

Miravitlles, M ;

Korducki, L ;

Towse, L ;

Kesten, S .

THORAX, 2003, 58 (05) :399-404

[6]

Bundschuh DS, 2001, J PHARMACOL EXP THER, V297, P280

[7] Improvement in exercise tolerance with the combination of tiotropium and pulmonary rehabilitation in patients with COPD [J].

Casaburi, R ;

Kukafka, D ;

Cooper, CB ;

Witek, TJ ;

Kesten, S .

CHEST, 2005, 127 (03) :809-817

[8] A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease [J].

Casaburi, R ;

Mahler, DA ;

Jones, PW ;

Wanner, A ;

San Pedro, G ;

ZuWallack, RL ;

Menjoge, SS ;

Serby, CW ;

Witek, T .

EUROPEAN RESPIRATORY JOURNAL, 2002, 19 (02) :217-224

[9] The spirometric efficacy of once-daily dosing with tiotropium in stable COPD - A 13-week multicenter trial [J].

Casaburi, R ;

Briggs, DD ;

Donohue, JF ;

Serby, CW ;

Menjoge, SS ;

Witek, TJ .

CHEST, 2000, 118 (05) :1294-1302

[10] Maintenance of asthma control by once-daily inhaled ciclesonide in adults with persistent asthma [J].

Chapman, KR ;

Patel, P ;

D'Urzo, AD ;

Alexander, M ;

Mehra, S ;

Oedekoven, C ;

Engelstätter, R ;

Boulet, LP .

ALLERGY, 2005, 60 (03) :330-337

← 1 2 3 4 5 6 →